Are you suffering from neuropathy? Stem cell therapy is showing promise as a solution for neuropathic pain. Learn more here.
Scientific Review: Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients
GIOSTAR leaders recently wrote on the potential benefits of stem cells in combating COVID-19. Published in Stem Cell Reviews and Reports, the review was written by Drs. Anand Srivastava, Prabhat Soni, Diana Esquivel, Rangnath Mishra, Rajasekar Seetharaman, and Anjum Mahmood
GIOSTAR recently treated a patient suffering from COVID-19 with stem cells. He experienced considerable improvement following this procedure. A placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.
Dr. Anand Srivastava, Deven Patel, Dr. Amy Killen, and Dr. Kyle Bergquist take part in a fascinating mini-documentary entitled Age of Cells. The program features extensive interviews with Dr. Srivastava and Mr. Patel, excerpts from lectures, and a sweeping tour of India.
Learn more about multiple sclerosis, and how stem cell therapy may provide symptomatic relief for patients suffering from this neurodegenerative disease.
GIOSTAR Chairman and Co-Founder Dr. Anand Srivastava recently spoke with Healthcare Weekly about stem cells, COVID-19, and numerous other topics.
GIOSTAR continues exploring new strategies for managing the world’s most debilitating diseases. Most recently, Dr. Anand Srivastava conducted research on the use of an Ayurvedic medicinal product to address diabetes.
Under the direction of GIOSTAR Co-Founder Dr. Anand Srivastava, a patient was treated with a topical application of mesenchymal stem cells. Remarkably, the patient saw their psoriasis regress completely after only one month.
Editorial: Mesenchymal stem cells may be a credible alternative therapy to fight with COVID-19 pandemic
Drs. Anand Srivastava and Prabhat Soni write in a medical journal on the potential benefits of stem cells in fighting against COVID-19. GIOSTAR recently received FDA Approval Under Compassionate Use to treat COVID-19 patients under compassionate use.